Proper Dosage of Ketamine in Intravenous Regional Anesthesia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00221871
Verified September 2005 by University Health Network, Toronto. Recruitment status was: Recruiting
Ketamine added to Lidocaine can increase duration of pain relief following intraveonous regional anesthesia (IVRA). The purpose of this dose response study is to determine the minimum effective dosage of intravenous Ketamine, added to 3 mg/kg of Lidocaine. We anticipate that one dosage will provide us with the proper balance between sufficient anesthesia and minimal side effects.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Weight: 50-100 kg
ASA: I, II, III
Carpal tunnel syndrome surgery, tenolysis, ganglion removal or any peripheral hand surgery that can be done by IVRA.
Contraindication to IVRA such as sickle cell disease.
Any known hypersensitivity reaction to Ketamine.
History of chronic pain or regular medication with analgesics.